دورية أكاديمية
Predictive modeling of adverse drug reactions to tamoxifen therapy for breast cancer on base of pharmacogenomic testing.
| العنوان: | Predictive modeling of adverse drug reactions to tamoxifen therapy for breast cancer on base of pharmacogenomic testing. |
|---|---|
| المؤلفون: | Golubenko EO; Department of Obstetrics and Gynecology, Russian Medical Academy of Continuous Professional Education of the Ministry of Health of Russia, Moscow, Russia., Savelyeva MI; Department of Therapy, Institute of Continuous Professional Education, Yaroslavl State Medical University of the Ministry of Health of Russia, Yaroslavl, Russia., Sozaeva ZA; Research Institute of Molecular and Personalized Medicine, Russian Medical Academy of Continuous Professional Education of the Ministry of Health of Russia, Moscow, Russia., Korennaya VV; Department of Obstetrics and Gynecology, Russian Medical Academy of Continuous Professional Education of the Ministry of Health of Russia, Moscow, Russia., Poddubnaya IV; Oncology Department, Russian Medical Academy of Continuous Professional Education of the Ministry of Health of Russia, Moscow, Russia., Valiev TT; Department of Pediatric Oncology and Hematology Research Institute, Blokhin' National Medical Research Cancer Center of the Ministry of Health of Russia, Moscow, Russia., Kondratenko SN; Department of Clinical Pharmacology and Propaedeutics of Internal Diseases, Sechenov' First Moscow State Medical University of the Ministry of Health of Russia, Moscow, Russia., Ilyin MV; Department of Therapy, Institute of Continuous Professional Education, Yaroslavl State Medical University of the Ministry of Health of Russia, Yaroslavl, Russia. |
| المصدر: | Drug metabolism and personalized therapy [Drug Metab Pers Ther] 2023 Jul 20; Vol. 38 (4), pp. 339-347. Date of Electronic Publication: 2023 Jul 20 (Print Publication: 2023). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: De Gruyter Country of Publication: Germany NLM ID: 101653409 Publication Model: eCollection Cited Medium: Internet ISSN: 2363-8915 (Electronic) Linking ISSN: 23638915 NLM ISO Abbreviation: Drug Metab Pers Ther Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Berlin : De Gruyter, [2015]- |
| مواضيع طبية MeSH: | Breast Neoplasms*/drug therapy , Breast Neoplasms*/genetics , Drug-Related Side Effects and Adverse Reactions*/genetics, Humans ; Female ; Cytochrome P-450 CYP2D6/genetics ; Cytochrome P-450 CYP3A/genetics ; Cytochrome P-450 CYP2C19/genetics ; Pharmacogenomic Testing ; Cytochrome P-450 CYP2C9/genetics ; Genotype ; Tamoxifen/adverse effects |
| مستخلص: | Objectives: The present study investigated the analysis of adverse drug reactions (ADRs) to tamoxifen (TAM) in breast cancer patients in relation to the carriage of genetic polymorphisms of genes encoding enzymes of CYP system and transporters of P-glycoprotein (Pg) and predictive models based on it. Methods: A total of 120 women with breast cancer taking adjuvant TAM were examined for the gene polymorphisms such as CYP2D6*4 , CYP3A5*3 , CYP2C9*2 , CYP2C9*3 , CYP2C19*2 , CYP2C19*3 and ABCB1 ( C3435T ). Allelic variants were determined using the real-time polymerase chain reaction method. The research material was double sampling of buccal epithelium. Medical history data and extracts from case histories were used as sources of medical information, on the basis of which questionnaires specially created by us were filled out. Results: An associative analysis showed association with the development of ADRs to TAM indicating their clinical significance from different genetic polymorphisms of CYP2D6 , CYP3A5 , CYP2C9 and ABCB1 . The complex associative analysis performed using mathematical modeling made it possible to build predictive risk models for the development of ADRs such as hot flashes, dyspepsia, bone pain, and asthenia. Conclusions: Models that include both genetic and non-genetic determinants of ADRs of TAM may further improve the prediction of individual response to TAM. (© 2023 Walter de Gruyter GmbH, Berlin/Boston.) |
| References: | Siegel, RL, Miller, KD, Jemal, A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7–30. https://doi.org/10.3322/caac.21590 . (PMID: 10.3322/caac.21590) Huang, B, Warner, M, Gustafsson, JA. Estrogen receptors in breast carcinogenesis and endocrine therapy. Mol Cell Endocrinol 2015;418:240–4. https://doi.org/10.1016/j.mce.2014.11.015 . (PMID: 10.1016/j.mce.2014.11.015) Rugo, HS, Rumble, RB, Macrae, E, Barton, DL, Connolly, HK, Dickler, MN, et al.. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American society of clinical oncology guideline. J Clin Oncol 2016;34:3069–103. https://doi.org/10.1200/jco.2016.67.1487 . (PMID: 10.1200/jco.2016.67.1487) Sanchez-Spitman, AB, Swen, JJ, Dezentje, VO, Moes, DJAR, Gelderblom, H, Guchelaar, HJ. Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen. Expet Rev Clin Pharmacol 2019;12:523–36. https://doi.org/10.1080/17512433.2019.1610390 . (PMID: 10.1080/17512433.2019.1610390) Brauch, H, Murdter, TE, Eichelbaum, M, Schwab, M. Pharmacogenomics of tamoxifen therapy. Clin Chem 2009;55:1770–82. https://doi.org/10.1373/clinchem.2008.121756 . (PMID: 10.1373/clinchem.2008.121756) Relling, MV, Klein, TE. CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research net-work. Clin Pharmacol Ther 2011;89:464–7. https://doi.org/10.1038/clpt.2010.279 . (PMID: 10.1038/clpt.2010.279) Knox, SK, Ingle, JN, Suman, VJ, Rae, JM, Flockhart, DA, Desta, Z, et al.. Cytochrome P450 2D6 status predicts breast cancer relapse in women receiving adjuvant tamoxifen (Tam). J Clin Oncol 2006;24:4S. https://doi.org/10.1200/jco.2006.24.18_suppl.504 . (PMID: 10.1200/jco.2006.24.18_suppl.504) Saladores, P, Mürdter, T, Eccles, D, Chowbay, B, Zgheib, NK, Winter, S, et al.. Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer. Pharmacogenomics J 2015;15:84–94. https://doi.org/10.1038/tpj.2014.34 . (PMID: 10.1038/tpj.2014.34) Schroth, W, Goetz, MP, Hamann, U, Fasching, PA, Schmidt, M, Winter, S, et al.. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009;302:1429–36. https://doi.org/10.1001/jama.2009.1420 . (PMID: 10.1001/jama.2009.1420) Sanchez-Spitman, A, Dezentje, V, Swen, J, Moes, DJAR, Böhringer, S, Batman, E, et al.. Tamoxifen pharmacogenetics and metabolism: results from the prospective CYPTAM study. J Clin Oncol 2019;37:636–46. https://doi.org/10.1200/jco.18.00307 . (PMID: 10.1200/jco.18.00307) Binkhorst, L, Mathijssen, RH, Jager, A, van Gelder, T. Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping. Cancer Treat Rev 2015;41:289–99. https://doi.org/10.1016/j.ctrv.2015.01.002 . (PMID: 10.1016/j.ctrv.2015.01.002) Thompson, AM, Johnson, A, Quinlan, P, Hillman, G, Fontecha, M, Bray, SE, et al.. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat 2011;125:279–87. https://doi.org/10.1007/s10549-010-1139-x . (PMID: 10.1007/s10549-010-1139-x) Joffe, H, Deckersbach, T, Lin, NU, Makris, N, Skaar, TC, Rauch, SL, et al.. Metabolic activity in the insular cortex and hypothalamus predicts hot flashes: an FDG-PET study. J Clin Endocrinol Metab 2012;97:3207–15. https://doi.org/10.1210/jc.2012-1413 . (PMID: 10.1210/jc.2012-1413) Conzen, SD, Lynn, HN. Managing the side effects of tamoxifen and aromatase inhibitors. Available from: https://www.uptodate.com/contents/managing-the-side-effects-of-tamoxifen-and-aromatase-inhibitors/print?search=tamoxifen [Accessed 13 Nov 2022]. Kedar, RP, Bourne, TH, Collins, WP, Campbell, S, Powles, TJ, Ashley, S, et al.. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 1994;343:1318–21. https://doi.org/10.1016/s0140-6736(94)92466-x . (PMID: 10.1016/s0140-6736(94)92466-x) Goetz, MP, Rae, JM, Suman, VJ, Safgren, SL, Ames, MM, Visscher, DW, et al.. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005;23:9312–8. https://doi.org/10.1200/jco.2005.03.3266 . (PMID: 10.1200/jco.2005.03.3266) Sensorn, I, Sukasem, C, Sirachainan, E, Chamnanphon, M, Pasomsub, E, Trachu, N, et al.. ABCB1 and ABCC2 and the risk of distant metastasis in Thai breast cancer patients treated with tamoxifen. OncoTargets Ther 2016;9:2121–9. https://doi.org/10.2147/ott.s100905 . (PMID: 10.2147/ott.s100905) Irvin, WJ, Walko, CM, Weck, KE, Ibrahim, JG, Chiu, WK, Dees, EC, et al.. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol Off J Am Soc Clin Oncol 2011;29:3232–9. https://doi.org/10.1200/jco.2010.31.4427 . (PMID: 10.1200/jco.2010.31.4427) Dean, L. Tamoxifen therapy and CYP2D6 genotype. Source medical genetics summaries [Internet] . Bethesda, MD: National Center for Biotechnology Information (US); 2012. 2014 Oct 7 [updated 2019 May 1] PMID: 28520357. Mwinyi, J, Vokinger, K, Jetter, A, Breitenstein, U, Hiller, C, Kullak-Ublick, GA, et al.. Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy. Cancer Chemother Pharmacol 2014;73:1181–8. https://doi.org/10.1007/s00280-014-2453-5 . (PMID: 10.1007/s00280-014-2453-5) Swen, JJ, Nijenhuis, M, de Boer, A, Grandia, L, Maitland-van der Zee, AH, Mulder, H, et al.. Pharmacogenetics: from bench to byte-an update of guidelines. Clin Pharmacol Ther 2011;89:662–73. https://doi.org/10.1038/clpt.2011.34 . (PMID: 10.1038/clpt.2011.34) Khan, BA, Robinson, R, Fohner, AE, Muzquiz, LI, Schilling, BD, Beans, JA, et al.. Cytochrome P450 genetic variation associated with tamoxifen biotransformation in American Indian and Alaska native people. Clin Transl Sci 2018;11:312–21. https://doi.org/10.1111/cts.12542 . (PMID: 10.1111/cts.12542) Cronin-Fenton, DP, Damkier, P. Tamoxifen and CYP2D6: a controversy in pharmacogenetics. Adv Pharmacol 2018;83:65–91. https://doi.org/10.1016/bs.apha.2018.03.001 . (PMID: 10.1016/bs.apha.2018.03.001) Chan, CWH, Law, BMH, So, WKW, Chow, KM, Waye, MMY. Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen. J Cancer Res Clin Oncol 2020;146:1395–404. https://doi.org/10.1007/s00432-020-03206-w . (PMID: 10.1007/s00432-020-03206-w) |
| فهرسة مساهمة: | Keywords: P-glycoprotein transporters; breast cancer; cytochromes P450; pharmacogenetics; polymorphism; tamoxifen |
| المشرفين على المادة: | EC 1.14.14.1 (Cytochrome P-450 CYP2D6) EC 1.14.14.1 (Cytochrome P-450 CYP3A) EC 1.14.14.1 (Cytochrome P-450 CYP2C19) EC 1.14.13.- (Cytochrome P-450 CYP2C9) 094ZI81Y45 (Tamoxifen) |
| تواريخ الأحداث: | Date Created: 20230719 Date Completed: 20240104 Latest Revision: 20240104 |
| رمز التحديث: | 20240104 |
| DOI: | 10.1515/dmpt-2023-0027 |
| PMID: | 37466310 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2363-8915 |
|---|---|
| DOI: | 10.1515/dmpt-2023-0027 |